June 11, 2020 / 11:34 AM / 2 months ago

BRIEF-Bioxcel Announces First Patient Enrolled In Phase 1B/2 Release For The Treatment Of Opioid Withdrawal Symptoms

June 11 (Reuters) - BioXcel Therapeutics Inc:

* BIOXCEL THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 1B/2 RELEASE TRIAL OF BXCL501 FOR THE TREATMENT OF OPIOID WITHDRAWAL SYMPTOMS

* BIOXCEL THERAPEUTICS - LOOK FORWARD TO REPORTING TOPLINE RESULTS FROM RELEASE BXCL501 STUDY IN Q1 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below